Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Physiomics (PYC) Share Price

Intraday
Historical

Price	0.48p on 07-05-2025 at 17:40:11
Change	0.035p 7.87%
Buy	0.50p
Sell	0.46p
Buy / Sell PYC Shares

Last Trade:	Sell 25,000.00 at 0.464p
Day's Volume:	8,408,824
Last Close:	0.48p
Open:	0.445p
ISIN:	GB00BDR6W943

Day's Range	0.445p - 0.48p
52wk Range:	0.39p - 1.50p
Market Capitalisation:	£1m
VWAP:	0.476473p
Shares in Issue:	303m

Sector: Medical Services

Listed In: FTSE AIM All-Share,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Physiomics (PYC) Latest Trades
Sell*	25,000	0.464p	Ordinary	16:15:47 - 07-May-25
Buy*	500,000	0.4822p	Ordinary	16:12:42 - 07-May-25
Buy*	405,693	0.492p	Ordinary	16:11:14 - 07-May-25
Buy*	98,988	0.494p	Ordinary	15:56:54 - 07-May-25
Buy*	30,000	0.4822p	Ordinary	15:42:15 - 07-May-25
Sell*	1,050	0.464p	Ordinary	15:26:52 - 07-May-25
Buy*	822,082	0.494p	Ordinary	15:16:45 - 07-May-25
Buy*	75,000	0.488p	Ordinary	15:12:50 - 07-May-25
Buy*	920,901	0.488p	Ordinary	15:02:25 - 07-May-25
Buy*	50,000	0.4805p	Ordinary	12:15:52 - 07-May-25

See more Physiomics trades

Physiomics (PYC) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
7th May 2025 (Wed)	0.445	0.48	0.445	0.48	8,408,824
6th May 2025 (Tue)	0.42	0.445	0.42	0.445	10,591,417
5th May 2025 (Mon)	0.402	0.402	0.402	0.402	0
2nd May 2025 (Fri)	0.425	0.425	0.42	0.42	2,281,590
1st May 2025 (Thu)	0.41	0.43	0.405	0.425	9,463,585
30th Apr 2025 (Wed)	0.425	0.425	0.405	0.41	7,980,888
29th Apr 2025 (Tue)	0.48	0.48	0.415	0.425	16,027,381
28th Apr 2025 (Mon)	0.44	0.48	0.44	0.48	11,105,117
25th Apr 2025 (Fri)	0.485	0.545	0.44	0.44	27,227,265
24th Apr 2025 (Thu)	0.41	0.55	0.41	0.485	133,961,974
23rd Apr 2025 (Wed)	0.395	0.41	0.395	0.41	9,221,259
22nd Apr 2025 (Tue)	0.395	0.395	0.395	0.395	611,965
21st Apr 2025 (Mon)	0.39	0.39	0.39	0.39	0
18th Apr 2025 (Fri)	0.39	0.39	0.39	0.39	0
17th Apr 2025 (Thu)	0.39	0.39	0.39	0.39	3,923,384
16th Apr 2025 (Wed)	0.39	0.39	0.39	0.39	336,486
15th Apr 2025 (Tue)	0.40	0.40	0.39	0.39	1,641,903
14th Apr 2025 (Mon)	0.405	0.405	0.395	0.395	6,933,804
11th Apr 2025 (Fri)	0.405	0.405	0.405	0.405	575,420
10th Apr 2025 (Thu)	0.395	0.405	0.395	0.405	3,267,524
9th Apr 2025 (Wed)	0.405	0.405	0.39	0.39	3,186,570
8th Apr 2025 (Tue)	0.405	0.405	0.405	0.405	1,191,238

See more Physiomics price history

Date	Source	Headline
Physiomics (PYC) Regulatory News
7th May 2025 4:45 pm	RNS	AIM Rule 17 and Schedule 2(g) Update
17th Apr 2025 7:00 am	RNS-R	Physiomics Awarded New Contract
16th Apr 2025 7:00 am	RNS-R	Publication of Peer Reviewed Article
15th Apr 2025 7:00 am	RNS-R	Contract Award
17th Mar 2025 7:00 am	RNS	Contract Award with new client
13th Mar 2025 7:00 am	RNS-R	IMC Presentation on Company Website
6th Mar 2025 7:00 am	RNS	Interim Results
28th Feb 2025 7:00 am	RNS	Notice of Results and Investor Presentation
20th Feb 2025 12:00 pm	RNS	Holding(s) in Company
17th Feb 2025 1:00 pm	RNS	Result of WRAP Retail Offer

See more Physiomics regulatory news

Physiomics (PYC) Share News

Physiomics extends long-term collaboration with Numab via new contract

15th Apr 2025 18:23

(Alliance News) - Physiomics PLC on Tuesday said it has secured a new contract with long-standing client Numab Therapeutics AG, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Read More

IN BRIEF: Physiomics secures GBP102,000 model development contract

17th Mar 2025 16:22

Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Secures contract worth GBP102,000 with a new UK-based biotech firm that is focused on developing antibody drug conjugates based therapies targeting difficult-to-treat cancers. Says the contract will see it develop a pharmacokinetic pharmacodynamic model to inform optimal dosing for the client's upcoming first-in-human trial. Expects the project to run from April until August this year. Chief Executive Peter Sargent says: "We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments." Read More

IN BRIEF: Physiomics eyes new contracts but half-year loss widens

6th Mar 2025 19:08

Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Pretax loss widens to GBP249,000 in the six months to December 31 compared with GBP235,000 a year prior as revenue dips 12% to GBP329,000 from GBP374,000. Highlights strong pipeline with four contracts won in the first half of the financial year. Based on these signed contracts, the company expects total income for the current financial year will be in line with market expectations, with additional contracted revenue projected into next year - year to June 2026. The company is "actively progressing" a number of late-stage opportunities, however, there is no guarantee that these contracts will be signed within the current financial year. Read More

EARNINGS AND TRADING: Tullow eyes non-core sales; Treatt backs outlook

31st Jan 2025 16:36

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Physiomics shares rise as dosing software project gains key approvals

8th Jan 2025 15:10

(Alliance News) - Physiomics PLC on Wednesday said its personalised dosing software project has now obtained the key approvals needed to progress with its observational trial. Read More

See more Physiomics news

FTSE 100 Latest

Value8,559.33

Change-38.09

Physiomics (PYC) Share Price

Login to your account